ACRS vs KIM · rev $3.6M vs P/E 27, rev $1.11B
Aclaris Therapeutics Inc (ACRS) versus Kimco Realty Corporation (KIM) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported KIM revenue for 2026-06-30 was $1.11B. Net income was $318.2M. Revenue was up 98.7% from 2026-03-31 to 2026-06-30. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
ACRS currently screens at market cap $615.9M. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Not investment advice. Open the ACRS and KIM stock pages for the full models.
Not investment advice.